Baupost Group Llc/Ma - Sep 14, 2021 Form 4/A - restatement Insider Report for Translate Bio, Inc. (TBIO)

Role
10%+ Owner
Signature
Seth A. Klarman
Stock symbol
TBIO
Transactions as of
Sep 14, 2021
Transactions value $
-$685,681,082
Form type
4/A - RESTATEMENT
Date filed
9/16/2021, 05:43 PM
Date Of Original Report
Jun 30, 2020
Previous filing
May 13, 2021
Next filing
Dec 14, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction TBIO Common Stock -Other -$685,681,082 -18,044,239 -100% $38.00 0 Sep 14, 2021 See footnote 1 and 2 F1, F2, F3

Explanation of Responses:

Id Content
F1 This statement on Form 4 is being jointly filed by The Baupost Group, L.L.C. ("Baupost"), Baupost Group GP, L.L.C. ("BG GP") and Seth A. Klarman ("Mr. Klarman") (collectively, the "Reporting Persons"). Baupost is a registered investment adviser. The principal business of Baupost is to act as an investment adviser to various private investment limited partnerships. BG GP, as the manager of Baupost, and Mr. Klarman, as the sole managing member of BG GP and a controlling person of Baupost, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), of the securities beneficially owned by Baupost. Securities reported on this Form 4 as being beneficially owned by Baupost were purchased on behalf of certain of such partnerships.
F2 (Continued from Footnote 1) The Reporting Persons disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that the Reporting Persons are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose.
F3 On September 14, 2021, the Agreement and Plan of Merger among Sanofi, Vector Merger Sub Inc. and Translate Bio Inc. ("Merger Agreement") was consummated and Sanofi completed its acquisition of the Issuer as described in the 8-K filed by the Issuer on September 14, 2021, and incorporated herein by reference. In connection with the consummation of the merger, all shares of Common Stock of the Issuer held by the Reporting Persons were acquired at the tender offer price of $38.00 per share.